Patents by Inventor Lidet A. Negash

Lidet A. Negash has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS
    Publication number: 20230114683
    Abstract: Disclosed are compounds of Formulas (I) or (II) or a salt thereof, wherein X, R1, R2, R3, and n are defined herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.
    Type: Application
    Filed: February 2, 2021
    Publication date: April 13, 2023
    Inventors: Saleem Ahmad, Lidet A. Negash
  • BENZO[5,6][1,4]DIOXINO[2,3-B]PYRIDINE COMPOUNDS USEFUL AS IRAK4 INHIBITORS
    Publication number: 20230101525
    Abstract: Disclosed are compounds of Formula (I) or a salt or prodrug thereof, wherein R1, R2, and R3 are defined herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.
    Type: Application
    Filed: February 2, 2021
    Publication date: March 30, 2023
    Inventors: Lidet A. Negash, Saleem Ahmad
  • BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS IRAK4 INHIBITORS
    Publication number: 20220281844
    Abstract: Disclosed are compounds of Formula (I) or a salt or prodrug thereof, wherein: X is CR4a or N; Y is CR4b or N; Z is CR4d or N; provided that zero or 1 of X, Y, and Z is N; and R1, R2, R3, R4a, R4b, R4c, and R4d are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.
    Type: Application
    Filed: August 5, 2020
    Publication date: September 8, 2022
    Inventors: Saleem Ahmad, Kandhasamy Sarkunam, Ling Li, Lidet A. Negash, John Hynes
  • Thienopyridines and benzothiophenes useful as IRAK4 inhibitors
    Patent number: 10829496
    Abstract: Disclosed are compounds of Formula (I) or a salt or prodrug thereof, wherein: X is CR4 or N; Y is CR5 or N; provided that only one of X and Y is N; (R1) is: or; wherein R1, R1a, R1b, R1c, R2, and R3 are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.
    Type: Grant
    Filed: May 10, 2018
    Date of Patent: November 10, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Saleem Ahmad, Ling Li, Lidet A. Negash, John Hynes
  • THIENOPYRIDINES AND BENZOTHIOPHENES USEFUL AS IRAK4 INHIBITORS
    Publication number: 20200062777
    Abstract: Disclosed are compounds of Formula (I) or a salt or prodrug thereof, wherein: X is CR4 or N; Y is CR5 or N; provided that only one of X and Y is N; (R1) is: or; wherein R1, R1a, R1b, R1c, R2, and R3 are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.
    Type: Application
    Filed: May 10, 2018
    Publication date: February 27, 2020
    Inventors: Saleem AHMAD, Ling Li, Lidet A. Negash, John Hynes
  • Dihydropyridinone MGAT2 inhibitors
    Patent number: 9822074
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: November 21, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Saleem Ahmad, Lidet A. Negash
  • DIHYDROPYRIDINONE MGAT2 INHIBITORS
    Publication number: 20170283381
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
    Type: Application
    Filed: June 9, 2017
    Publication date: October 5, 2017
    Inventors: Saleem Ahmad, Lidet A. Negash
  • DIHYDROPYRIDINONE MGAT2 INHIBITORS
    Publication number: 20160256445
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
    Type: Application
    Filed: May 13, 2016
    Publication date: September 8, 2016
    Inventors: Saleem Ahmad, Lidet A. Negash
  • Dihydropyridinone MGAT2 inhibitors
    Patent number: 9365558
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
    Type: Grant
    Filed: May 28, 2014
    Date of Patent: June 14, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Saleem Ahmad, Lidet A. Negash
  • Oxabicyclo [2.2.2] acid GPR120 modulators
    Patent number: 8962660
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR120 G protein-coupled receptor modulators which may be used as medicaments.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: February 24, 2015
    Assignee: Bristol-Myers Squibb Company
    Inventors: Hao Zhang, Peter T. W. Cheng, Sean Chen, Shiwei Tao, Shung C. Wu, Lidet A Negash
  • DIHYDROPYRIDINONE MGAT2 INHIBITORS
    Publication number: 20140357670
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
    Type: Application
    Filed: May 28, 2014
    Publication date: December 4, 2014
    Inventors: Saleem Ahmad, Lidet A. Negash
  • OXABICYCLO [2.2.2] ACID GPR120 MODULATORS
    Publication number: 20140275173
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR120 G protein-coupled receptor modulators which may be used as medicaments.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 18, 2014
    Inventors: Hao Zhang, Peter T.W. Cheng, Sean Chen, Shiwei Tao, Shung C. Wu, Lidet A. Negash